Prednisolone

證據等級: L5

預測適應症: 10 個

Prednisolone: From Systemic Anti-Inflammatory/Immunosuppressive Therapy to Alopecia Areata

One-Sentence Summary

Prednisolone is a systemic glucocorticoid traditionally used across a broad range of inflammatory, allergic, and autoimmune conditions (specific original-indication text is not available in this evidence pack). The TxGNN model's top-ranked prediction (of 10 candidate indications) is Alopecia Areata, with 18 clinical trials and 20 publications identified in the evidence pack, including at least one placebo-controlled RCT testing oral pulse prednisolone directly in this disease.

Quick Overview

Item	Content
Original Indication	Not available (no NZ license records; prednisolone is generally used as a systemic glucocorticoid for anti-inflammatory/immunosuppressive therapy)
Predicted New Indication	Alopecia Areata
TxGNN Prediction Score	99.99%
Evidence Level	L2
New Zealand Market Status	✗ Not Marketed
Number of Authorizations	0
Recommended Decision	Proceed with Guardrails

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available (DrugBank MOA query returned a data gap). Based on known pharmacology, prednisolone is a systemic glucocorticoid whose anti-inflammatory and immunosuppressive efficacy is well established across autoimmune and inflammatory conditions.

Alopecia areata (AA) is a T-cell-mediated autoimmune disease in which the immune system attacks hair follicles that normally enjoy immune privilege. Glucocorticoids act through broad immunosuppression — including inhibition of pro-inflammatory cytokines and suppression of T-cell activation — which can interrupt this autoimmune attack. This mechanistic link is direct and well-supported: corticosteroids, including oral pulse prednisolone/methylprednisolone regimens, are already used in real-world clinical practice for severe or treatment-resistant AA.

This is therefore best understood not as a novel mechanistic hypothesis but as validation of an existing off-label/guideline-supported practice pattern, which strengthens (rather than merely predicts) the case for the drug-disease pairing.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT01167946	Phase 4	Completed	42	Oral mega-pulse methylprednisolone (higher dose, more frequent pulses) evaluated in patients with severe, treatment-resistant alopecia areata (totalis/universalis/ophiasic types). Graded "A" relevance — same glucocorticoid class as prednisolone, direct disease match.
NCT07101471	N/A	Completed	296	Observational safety/efficacy study of tofacitinib in alopecia patients, with participants receiving tofacitinib with or without adjuvant prednisolone.
NCT01017510	N/A	Unknown	20	Compared two injection techniques (DERMOJET vs. conventional syringe) for corticosteroid delivery in alopecia areata; conventional treatment for AA includes topical, intralesional, or oral steroids.

Note: The evidence pack contains 18 clinical trial records in total for this indication; the majority (e.g., baricitinib, sirolimus, efavaleukin alfa, olaparib trials in SLE/prostate cancer) are not directly about alopecia areata or prednisolone and were graded "C"/"pending" for relevance — these are excluded above as non-informative for this specific pairing.

Literature Evidence

PMID	Year	Type	Journal	Key Findings
15692475	2005	RCT	J Am Acad Dermatol	Placebo-controlled RCT of oral pulse prednisolone therapy in alopecia areata — the only randomized, placebo-controlled study of systemic corticosteroids specifically in AA identified to date.
37870096	2023	Network Meta-analysis	Cochrane Database Syst Rev	Network meta-analysis of AA treatments, including immunosuppressants and corticosteroids, comparing relative efficacy.
37992355	2023	Review	Dermatol Pract Concept	Reviews efficacy, relapse rates, side effects, and prognostic factors of corticosteroid pulse therapy regimens in AA.
30191561	2019	Systematic Review	Australas J Dermatol	Systematic review of systemic treatments (1946–2018) for AA, alopecia totalis, and alopecia universalis, including RCT evidence.
35986630	2022	Retrospective Cohort	Dermatol Ther	Methylprednisolone alone vs. methylprednisolone + methotrexate in 26 patients with extensive AA; assessed whether combination therapy was superior.
36461625	2023	Cohort/Dosing Review	Pediatr Dermatol	Reviews pulse dose corticosteroid therapy regimens and associated side effects in pediatric AA.
28140540	2017	Case Series	J Dtsch Dermatol Ges	Sequential high- then low-dose systemic corticosteroid therapy in severe childhood AA; addresses relapse after discontinuation.
32779249	2020	Retrospective Cohort	J Eur Acad Dermatol Venereol	Retrospective study of steroid-sparing agents (azathioprine, methotrexate, cyclosporine) continuation rates in 138 chronic AA patients treated after prednisolone.
21572877	2009	Clinical Study	Dermatoendocrinol	Medium-dose prednisolone pulse therapy in AA; effective in early-stage disease but with notable side effects leading to discontinuation.
41243342	2025	Review	J Dermatolog Treat	Discusses corticosteroid pulse regimens (dexamethasone oral mini-pulse) as systemic alternatives when JAK inhibitors are inaccessible or contraindicated.

New Zealand Market Information

No marketing authorizations for prednisolone are currently registered in New Zealand (0 licenses on file; market status: Not Marketed).

Safety Considerations

Please refer to the package insert for safety information. (No key warnings, contraindications, or drug interaction data are currently available — TFDA/Medsafe package insert data, DDI database, and TFDA warning queries all returned no results.)

Conclusion and Next Steps

Decision: Proceed with Guardrails

Rationale: The mechanistic link between glucocorticoid immunosuppression and AA pathophysiology is strong, and one placebo-controlled RCT plus a Phase 4 trial and multiple cohort studies/reviews support oral pulse corticosteroid (including prednisolone) use in severe/refractory AA — this is an established off-label practice pattern rather than a purely novel hypothesis. However, evidence is heterogeneous (mostly small cohorts/case series with only one direct RCT), and critical safety and regulatory data for this specific drug are missing.

To proceed, the following is needed:

TFDA/Medsafe package insert warnings, contraindications, and drug interaction data (currently a Blocking data gap — required before any S1 safety assessment)
Confirmed mechanism of action data from DrugBank (currently a data gap)
A defined pulse-dosing and monitoring protocol specific to AA (dose, frequency, duration, tapering, relapse monitoring)
Assessment of regulatory pathway given the drug is not currently marketed in New Zealand
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.